Supplementary Figure 5 from SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1-, or EGFR-altered Non–small Cell Lung Cancer

MLA

Katsuyuki Kiura, et al. Supplementary Figure 5 from SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-Naïve ALK-, ROS1-, or EGFR-Altered Non–small Cell Lung Cancer. Apr. 2023. EBSCOhost, https://doi.org/10.1158/1535-7163.22522918.

APA

Katsuyuki Kiura, Yoshinobu Maeda, Masahiro Tabata, Katsuyuki Hotta, Kadoaki Ohashi, Kammei Rai, Toshio Kubo, Yuka Kato, Kiichiro Ninomiya, Takamasa Nakasuka, Chihiro Ando, Kazuya Nishii, Hiromi Watanabe, Eiki Ichihara, & Hirohisa Kano. (2023). Supplementary Figure 5 from SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1-, or EGFR-altered Non–small Cell Lung Cancer. https://doi.org/10.1158/1535-7163.22522918

Chicago

Katsuyuki Kiura, Yoshinobu Maeda, Masahiro Tabata, Katsuyuki Hotta, Kadoaki Ohashi, Kammei Rai, Toshio Kubo, et al. 2023. “Supplementary Figure 5 from SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-Naïve ALK-, ROS1-, or EGFR-Altered Non–small Cell Lung Cancer,” April. doi:10.1158/1535-7163.22522918.